Press Releases

Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced

Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated labs MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies,

MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Canaccord Genuity 46 th Annual Growth Conference on Tuesday, August 11,

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight MENLO PARK, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer

MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies’ Global Healthcare Conference on Thursday, June 4, 2026, at

Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers MENLO PARK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies,

MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026. Recent Business Highlights Selected by Basecamp Research to power its Trillion Gene Atlas, which is expected to result in approximately 100,000 samples

Expands access to streamlined genomic data analysis across the PacBio partner ecosystem MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics software for